Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00805467 · ClinicalTrials.gov registry record · Phase 2
Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 624
- Enrollment target
NCT00805467 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 624 participants.
The verdict
NCT00805467, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 624 participants
- Enrollment target
Study Summary
The purpose of this new research study is to gain additional information about how safe and effective R935788 is over a longer period of time.
Interventions
- DRUG Fostamatinib Disodium (R935788)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 624 participants |
| Start Date | 2008-08 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00805467
The ClinicalTrials.gov registry entry for NCT00805467 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 624 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fostamatinib Disodium (R935788) is the first listed.
NCT00805467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00805467 about?
NCT00805467 is a clinical study titled "Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies". The purpose of this new research study is to gain additional information about how safe and effective R935788 is over a longer period of time.
What is the current status of trial NCT00805467?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 624 participants. The study started on 2008-08. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00805467?
The interventions under investigation include: Fostamatinib Disodium (R935788) (DRUG).
Who is sponsoring clinical trial NCT00805467?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.